| |
|
|
|
Xtalks, Online
2025-05-20
The global obesity epidemic has driven demand for innovative treatments, creating a competitive and rapidly evolving landscape in obesity drug development. While media coverage has amplified interest and sensationalized the use of GLP-1 receptor agonists, gaps remain in addressing unmet needs and improving current approved treatments for patients1.
This webinar will explore the obesity drug landscape, highlighting how the industry is responding to leading therapies and identifying opportunities for future innovation. The expert speakers will discuss alternative mechanisms of action that expand therapeutic possibilities beyond GLP-1 receptor agonists, offering hope for more effective solutions.
Additionally, the expert speakers will examine critical operational challenges in obesity drug clinical trials, including recruitment hurdles, psychological barriers and the importance of holistic patient support. By integrating psychological care and addressing social stigmas, the standard of care for patients managing obesity can be improved.
Join this webinar to navigate the evolving obesity treatment landscape, uncover practical solutions to trial challenges and pave the way for more effective therapies.
Source: 1Gionfriddo, Michael R. et al. An analysis of national news coverage of semaglutide for weight loss. Journal of the American Pharmacists Association, Volume 65, Issue 1, 102297.
Keywords: Clinical Trials, Obesity, Drug Development, Clinical Research, CRO, Therapeutics, Patient Engagement, Biotherapeutics, GLP-1, GLP-1 Agonist, Obesity Drug, GLP-1 Agonists, GLP-1 Drugs
|
|
|
|
|
|
|
|
Organized by:
|
|
Xtalks |
|
|
Invited Speakers:
|
|
Ana Gonzalez-Santis, PhD, PMP, Executive Director, Program Strategy, General Medicine, Premier Research
|
|
|
|
|
|
|
|
Deadline for Abstracts:
|
|
2025-05-20
|
|
|
|
|
|
|
|
Registration:
|
|
Free Registration
|
|
|
E-mail:
|
|
tristan@xtalks.com
|
|
|
|
|
|
|
|
|
|
|
|
|